MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
3.570
+0.180
+5.31%
Closed 19:04 02/06 EST
OPEN
3.360
PREV CLOSE
3.390
HIGH
3.650
LOW
3.300
VOLUME
1.57M
TURNOVER
0
52 WEEK HIGH
4.890
52 WEEK LOW
1.050
MARKET CAP
386.79M
P/E (TTM)
-2.5868
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRS last week (0202-0206)?
Weekly Report · 3h ago
Aclaris Therapeutics nimmt an zwei Healthcare-Konferenzen teil
Reuters · 5d ago
Aclaris Therapeutics to Present at Major Healthcare Conferences
Reuters · 5d ago
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump
Simply Wall St · 6d ago
Weekly Report: what happened at ACRS last week (0126-0130)?
Weekly Report · 02/02 09:07
Aclaris Therapeutics initiated with a Buy at Craig-Hallum
TipRanks · 01/30 12:11
Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy
TipRanks · 01/30 12:10
Looking Into Aclaris Therapeutics Inc's Recent Short Interest
Benzinga · 01/29 13:00
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.